Methylcantharidimide

DB18959InvestigationalSmall molecule

Methylcantharidimide is under investigation in clinical trial NCT03996681 (TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma).

Formula / weight: C₁₁H₁₅NO₃ · 209.245 g/mol (avg)
Also known as: 4,7-EPOXY-1H-ISOINDOLE-1,3(2H)-DIONE, HEXAHYDRO-2,3A,7A-TRIMETHYL-, (3AR,4S,7R,7AS)-REL- · N-methylcantharidimide

Resolves to

Compound

UNII62T9S2Y75ECAS76970-78-0

Structure

InChIKeyWUQNOBSCYAIJIH-FIPCFZRWSA-NSMILESCN1C(=O)[C@@]2(C)[C@@H]3CC[C@@H](O3)[C@@]2(C)C1=O

What you can answer from here — as of April 02, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Methylcantharidimide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account